Cancer in children is relatively rare. Yet, in 2014, 15,780 US adolescents, up to age 19 were diagnosed with some type of cancer. Most distressing of all, an estimated 1,960 of those cases were fatal. While survival rates have improved in the last fifty years, certain types of cancers, like brain tumors, still have lower survival rates. That’s why it is heartening to know that at the close of Childhood Cancer Awareness Month, the biopharmaceutical company DelMar Pharmaceuticals, Inc. (DMPI) has a cancer drug already in Phase I/II trials that may prove to be a ray of hope for young patients and their families.
The Vancouver-based company announced today that it will present the abstract, "Dianhydrogalactitol (VAL-083) Offers Potential Therapeutic Alternatives in the Treatment of Pediatric Brain Tumors," during this year’s American Association for Cancer Research (AACR) conference. The AACR is being held November 9-12, 2015 in Fort Lauderdale, FL.
Del Mar Continues to See Positive Results with VAL-083
This year’s AACR conference, “Advances in Pediatric Research: From Mechanisms and Models to Treatment and Survivorship,” will feature presentations and recent research that address the unique challenges in investigating the cause of childhood cancers. Del Mar’s presentation, scheduled for Tuesday, November 10th, will provide a summary of the effectiveness of VAL-083 in treating malignant pediatric brain tumors, along with the history of Del Mar’s recent research sponsored by the US National Cancer Institute.
Del Mar’s upcoming presentation at the AACR follows the company’s recent announcement of positive results from updated clinical data during their Phase I/II study of the effects of VAL-083 in patients diagnosed with GBM at the GBM 2015. VAL-083, in over 40 Phase I and II clinical studies, is a small molecule chemotherapeutic that has proven to be safe and effective in treating various cancers. While VAL-083 is in clinical trials in the United States, VAL-083 is approved and currently used in China to treat lung cancer.
This year, Childhood Cancer Awareness Month can close on a hopeful note. Through Del Mar Pharmaceutical’s dedication to develop and commercialize proven cancer therapies, the medical field is one step closer to providing effective treatment to the nation’s youngest patients.
For more information about Del Mar Pharmaceuticals, visit www.delmarpharma.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer